tiprankstipranks
Trending News
More News >
Iovance Biotherapeutics (IOVA)
:IOVA
US Market
Advertisement

Iovance Biotherapeutics (IOVA) Stock Forecast & Price Target

Compare
3,663 Followers
See the Price Targets and Ratings of:

IOVA Analyst Ratings

Moderate Buy
11Ratings
Moderate Buy
6 Buy
4 Hold
1 Sell
Based on 11 analysts giving stock ratings to
Iovance
Biotherapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

IOVA Stock 12 Month Forecast

Average Price Target

$8.90
▲(237.12% Upside)
Based on 11 Wall Street analysts offering 12 month price targets for Iovance Biotherapeutics in the last 3 months. The average price target is $8.90 with a high forecast of $25.00 and a low forecast of $1.00. The average price target represents a 237.12% change from the last price of $2.64.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","13":"$13","26":"$26","6.5":"$6.5","19.5":"$19.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,6.5,13,19.5,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.68,4.396923076923077,6.113846153846154,7.830769230769231,9.547692307692309,11.264615384615384,12.981538461538461,14.698461538461538,16.415384615384617,18.132307692307695,19.84923076923077,21.566153846153846,23.283076923076923,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.68,3.1584615384615384,3.636923076923077,4.115384615384616,4.593846153846155,5.072307692307692,5.550769230769231,6.02923076923077,6.507692307692308,6.986153846153847,7.464615384615385,7.943076923076923,8.421538461538463,{"y":8.9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.68,2.550769230769231,2.4215384615384616,2.2923076923076926,2.163076923076923,2.033846153846154,1.9046153846153848,1.7753846153846156,1.6461538461538463,1.516923076923077,1.3876923076923078,1.2584615384615385,1.1292307692307695,{"y":1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.16,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.66,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.35,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.19,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.07,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.4,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.85,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.24,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.25,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.33,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.76,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.74,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.68,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$25.00Average Price Target$8.90Lowest Price Target$1.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on IOVA
TipRanks AITipRanks
Not Ranked
TipRanks
$2.5
Hold
-5.30%
Downside
Reiterated
08/08/25
Iovance Biotherapeutics shows potential with significant revenue growth and strategic market expansion. However, ongoing profitability challenges and negative cash flow weigh heavily on the overall score. The technical analysis and valuation indicate mixed signals, while recent corporate events provide a cautiously optimistic outlook.
Wells Fargo Analyst forecast on IOVA
Yanan ZhuWells Fargo
Wells Fargo
$18$14
Buy
430.30%
Upside
Reiterated
08/08/25
Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Iovance Biotherapeutics (IOVA)
Barclays Analyst forecast on IOVA
Peter LawsonBarclays
Barclays
$4
Buy
51.52%
Upside
Reiterated
08/08/25
Barclays Reaffirms Their Buy Rating on Iovance Biotherapeutics (IOVA)
Truist Financial Analyst forecast on IOVA
Asthika GoonewardeneTruist Financial
Truist Financial
Hold
Reiterated
08/08/25
Truist Financial Keeps Their Hold Rating on Iovance Biotherapeutics (IOVA)
H.C. Wainwright Analyst forecast on IOVA
Joseph PantginisH.C. Wainwright
H.C. Wainwright
$20
Buy
657.58%
Upside
Reiterated
08/08/25
Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (NASDAQ: AVTX), Iovance Biotherapeutics (NASDAQ: IOVA) and NextCure (NASDAQ: NXTC)
TD Cowen
$5
Buy
89.39%
Upside
Reiterated
08/07/25
Iovance Biotherapeutics: Overcoming Revenue Shortfalls with Strategic Growth Initiatives
Goldman Sachs Analyst forecast on IOVA
Andrea NewkirkGoldman Sachs
Goldman Sachs
$1
Sell
-62.12%
Downside
Downgraded
07/15/25
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (NASDAQ: IOVA) and Eli Lilly & Co (NYSE: LLY)
Citizens JMP Analyst forecast on IOVA
Reni BenjaminCitizens JMP
Citizens JMP
Hold
Reiterated
07/15/25
Citizens JMP Keeps Their Hold Rating on Iovance Biotherapeutics (IOVA)
UBS
$2
Hold
-24.24%
Downside
Downgraded
05/16/25
Cautious Outlook for Iovance Biotherapeutics Amid Amtagvi Sales Challenges
Chardan Capital Analyst forecast on IOVA
Geulah LivshitsChardan Capital
Chardan Capital
$30$25
Buy
846.97%
Upside
Reiterated
05/09/25
Iovance Biotherapeutics price target lowered to $25 from $30 at ChardanIovance Biotherapeutics price target lowered to $25 from $30 at Chardan
Robert W. Baird Analyst forecast on IOVA
Colleen M. KusyRobert W. Baird
Robert W. Baird
$20$3
Hold
13.64%
Upside
Downgraded
05/09/25
Baird downgrades Iovanace Biotherapeutics (IOVA) to NeutralBaird analyst Colleen Kusy downgraded Iovanace Biotherapeutics (NASDAQ: IOVA) from Outperform to Neutral with a price target of $3.00 (from $20.00).
Mizuho Securities Analyst forecast on IOVA
Salim SyedMizuho Securities
Mizuho Securities
$30$10
Buy
278.79%
Upside
Reiterated
05/09/25
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (NASDAQ: IOVA), GH Research (NASDAQ: GHRS) and NewAmsterdam Pharma Company (NASDAQ: NAMS)
Guggenheim Analyst forecast on IOVA
Kelsey GoodwinGuggenheim
Guggenheim
Hold
Reiterated
04/01/25
Stifel Nicolaus Analyst forecast on IOVA
Benjamin BurnettStifel Nicolaus
Stifel Nicolaus
$18
Buy
581.82%
Upside
Reiterated
03/17/25
Iovance Biotherapeutics (IOVA) Receives a Buy from Stifel Nicolaus
Jefferies Analyst forecast on IOVA
Michael YeeJefferies
Jefferies
$23$18
Buy
581.82%
Upside
Reiterated
03/13/25
Iovanace Biotherapeutics (IOVA) PT Lowered to $18 at JefferiesJefferies analyst Michael Yee lowered the price target on Iovanace Biotherapeutics (NASDAQ: IOVA) to $18.00 (from $23.00) while maintaining a Buy rating.
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on IOVA
TipRanks AITipRanks
Not Ranked
TipRanks
$2.5
Hold
-5.30%
Downside
Reiterated
08/08/25
Iovance Biotherapeutics shows potential with significant revenue growth and strategic market expansion. However, ongoing profitability challenges and negative cash flow weigh heavily on the overall score. The technical analysis and valuation indicate mixed signals, while recent corporate events provide a cautiously optimistic outlook.
Wells Fargo Analyst forecast on IOVA
Yanan ZhuWells Fargo
Wells Fargo
$18$14
Buy
430.30%
Upside
Reiterated
08/08/25
Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Iovance Biotherapeutics (IOVA)
Barclays Analyst forecast on IOVA
Peter LawsonBarclays
Barclays
$4
Buy
51.52%
Upside
Reiterated
08/08/25
Barclays Reaffirms Their Buy Rating on Iovance Biotherapeutics (IOVA)
Truist Financial Analyst forecast on IOVA
Asthika GoonewardeneTruist Financial
Truist Financial
Hold
Reiterated
08/08/25
Truist Financial Keeps Their Hold Rating on Iovance Biotherapeutics (IOVA)
H.C. Wainwright Analyst forecast on IOVA
Joseph PantginisH.C. Wainwright
H.C. Wainwright
$20
Buy
657.58%
Upside
Reiterated
08/08/25
Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (NASDAQ: AVTX), Iovance Biotherapeutics (NASDAQ: IOVA) and NextCure (NASDAQ: NXTC)
TD Cowen
$5
Buy
89.39%
Upside
Reiterated
08/07/25
Iovance Biotherapeutics: Overcoming Revenue Shortfalls with Strategic Growth Initiatives
Goldman Sachs Analyst forecast on IOVA
Andrea NewkirkGoldman Sachs
Goldman Sachs
$1
Sell
-62.12%
Downside
Downgraded
07/15/25
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (NASDAQ: IOVA) and Eli Lilly & Co (NYSE: LLY)
Citizens JMP Analyst forecast on IOVA
Reni BenjaminCitizens JMP
Citizens JMP
Hold
Reiterated
07/15/25
Citizens JMP Keeps Their Hold Rating on Iovance Biotherapeutics (IOVA)
UBS
$2
Hold
-24.24%
Downside
Downgraded
05/16/25
Cautious Outlook for Iovance Biotherapeutics Amid Amtagvi Sales Challenges
Chardan Capital Analyst forecast on IOVA
Geulah LivshitsChardan Capital
Chardan Capital
$30$25
Buy
846.97%
Upside
Reiterated
05/09/25
Iovance Biotherapeutics price target lowered to $25 from $30 at ChardanIovance Biotherapeutics price target lowered to $25 from $30 at Chardan
Robert W. Baird Analyst forecast on IOVA
Colleen M. KusyRobert W. Baird
Robert W. Baird
$20$3
Hold
13.64%
Upside
Downgraded
05/09/25
Baird downgrades Iovanace Biotherapeutics (IOVA) to NeutralBaird analyst Colleen Kusy downgraded Iovanace Biotherapeutics (NASDAQ: IOVA) from Outperform to Neutral with a price target of $3.00 (from $20.00).
Mizuho Securities Analyst forecast on IOVA
Salim SyedMizuho Securities
Mizuho Securities
$30$10
Buy
278.79%
Upside
Reiterated
05/09/25
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (NASDAQ: IOVA), GH Research (NASDAQ: GHRS) and NewAmsterdam Pharma Company (NASDAQ: NAMS)
Guggenheim Analyst forecast on IOVA
Kelsey GoodwinGuggenheim
Guggenheim
Hold
Reiterated
04/01/25
Stifel Nicolaus Analyst forecast on IOVA
Benjamin BurnettStifel Nicolaus
Stifel Nicolaus
$18
Buy
581.82%
Upside
Reiterated
03/17/25
Iovance Biotherapeutics (IOVA) Receives a Buy from Stifel Nicolaus
Jefferies Analyst forecast on IOVA
Michael YeeJefferies
Jefferies
$23$18
Buy
581.82%
Upside
Reiterated
03/13/25
Iovanace Biotherapeutics (IOVA) PT Lowered to $18 at JefferiesJefferies analyst Michael Yee lowered the price target on Iovanace Biotherapeutics (NASDAQ: IOVA) to $18.00 (from $23.00) while maintaining a Buy rating.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Iovance Biotherapeutics

1 Month
xxx
Success Rate
14/32 ratings generated profit
44%
Average Return
+2.63%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 43.75% of your transactions generating a profit, with an average return of +2.63% per trade.
3 Months
xxx
Success Rate
9/16 ratings generated profit
56%
Average Return
+11.97%
reiterated a xxx
rating 18 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 56.25% of your transactions generating a profit, with an average return of +11.97% per trade.
1 Year
Geulah LivshitsChardan Capital
Success Rate
14/32 ratings generated profit
44%
Average Return
+9.19%
reiterated a buy rating 3 months ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 43.75% of your transactions generating a profit, with an average return of +9.19% per trade.
2 Years
xxx
Success Rate
7/32 ratings generated profit
22%
Average Return
-32.85%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 21.88% of your transactions generating a profit, with an average return of -32.85% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IOVA Analyst Recommendation Trends

Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
15
16
14
15
8
Buy
3
1
1
1
1
Hold
3
9
12
20
16
Sell
0
1
1
2
1
Strong Sell
0
0
0
0
0
total
21
27
28
38
26
In the current month, IOVA has received 9 Buy Ratings, 16 Hold Ratings, and 1 Sell Ratings. IOVA average Analyst price target in the past 3 months is 8.90.
Each month's total comprises the sum of three months' worth of ratings.

IOVA Financial Forecast

IOVA Earnings Forecast

Next quarter’s earnings estimate for IOVA is -$0.25 with a range of -$0.30 to -$0.21. The previous quarter’s EPS was -$0.33. IOVA beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 42.86% of the time in the same period. In the last calendar year IOVA has Preformed in-line its overall industry.
Next quarter’s earnings estimate for IOVA is -$0.25 with a range of -$0.30 to -$0.21. The previous quarter’s EPS was -$0.33. IOVA beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 42.86% of the time in the same period. In the last calendar year IOVA has Preformed in-line its overall industry.

IOVA Sales Forecast

Next quarter’s sales forecast for IOVA is $76.22M with a range of $70.00M to $84.20M. The previous quarter’s sales results were $59.95M. IOVA beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 37.45% of the time in the same period. In the last calendar year IOVA has Preformed in-line its overall industry.
Next quarter’s sales forecast for IOVA is $76.22M with a range of $70.00M to $84.20M. The previous quarter’s sales results were $59.95M. IOVA beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 37.45% of the time in the same period. In the last calendar year IOVA has Preformed in-line its overall industry.

IOVA Stock Forecast FAQ

What is IOVA’s average 12-month price target, according to analysts?
Based on analyst ratings, Iovance Biotherapeutics’s 12-month average price target is 8.90.
    What is IOVA’s upside potential, based on the analysts’ average price target?
    Iovance Biotherapeutics has 237.12% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is IOVA a Buy, Sell or Hold?
          Iovance Biotherapeutics has a consensus rating of Moderate Buy which is based on 6 buy ratings, 4 hold ratings and 1 sell ratings.
            What is Iovance Biotherapeutics’s price target?
            The average price target for Iovance Biotherapeutics is 8.90. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $25.00 ,the lowest forecast is $1.00. The average price target represents 237.12% Increase from the current price of $2.64.
              What do analysts say about Iovance Biotherapeutics?
              Iovance Biotherapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of IOVA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis